

Abstract of the Disclosure

Novel antagonists of the chemokine CXCL8 (also known as Interleukin-8) can be obtained by generating mutants having specific combinations of non-conservative substitutions of basic amino acids located in the C-terminal region. Compounds prepared in accordance with the present invention can be used to block CXCL8 activity *in vivo*, thereby providing therapeutic compositions for use in the treatment or prevention of CXCL8-related diseases.